10th antibody industrial symposium: new developments in antibody and adoptive cell therapies

References

• Parthiban K, Perera RL, Sattar M, Huang Y, Mayle S, Masters E, Griffiths D, Surade S, Leah R, Dyson MR, et al. A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing. MAbs. 2019;11(5):884–12. PMID:31107136. doi:10.1080/19420862.2019.1618673.
   PubMed Web of Science ®Google Scholar
• Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, Thorsteinson N, Parthiban K, Jones PC, Sattar M, et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. 2020;12(1):1829335. PMID:33103593. doi:10.1080/19420862.2020.1829335.
   PubMed Web of Science ®Google Scholar
• Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022;40(5):494–508.e5. PMID:35452603. doi:10.1016/j.ccell.2022.04.001.
   PubMed Web of Science ®Google Scholar
• Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28(9):1848–59. PMID:36097221. doi:10.1038/s41591-022-01959-0.
   PubMed Web of Science ®Google Scholar
• Jin H, D’Urso V, Neuteboom B, McKenna SD, Schweickhardt R, Gross AW, Fomekong Nanfack Y, Paoletti A, Carter C, Toleikis L, et al. Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. OncoImmunology. 2021;10(1):1958590. PMID:34484871. doi:10.1080/2162402X.2021.1958590.
   PubMed Web of Science ®Google Scholar
• Blanco B, Compte M, Lykkemark S, Sanz L, Alvarez-Vallina L. T cell-redirecting strategies to ‘STAb’ tumors: beyond CARs and bispecific antibodies. Trends Immunol. 2019;40(3):243–57. PMID:30827461. doi:10.1016/j.it.2019.01.008.
   PubMed Web of Science ®Google Scholar
• Furtmann N, Schneider M, Spindler N, Steinmann B, Li Z, Focken I, Meyer J, Dimova D, Kroll K, Leuschner WD, et al. An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics. MAbs. 2021;13(1):1955433. PMID:34382900. doi:10.1080/19420862.2021.1955433.
   PubMed Web of Science ®Google Scholar
• Pekar L, Klausz K, Busch M, Valldorf B, Kolmar H, Wesch D, Oberg H-H, Krohn S, Boje AS, Gehlert CL, et al. Affinity maturation of B7-H6 translates into enhanced NK cell–mediated tumor cell lysis and improved proinflammatory cytokine release of bispecific immunoligands via NKp30 engagement. J Immunol. 2021;206(1):225–36. PMID:33268483. doi:10.4049/jimmunol.2001004.
   PubMed Web of Science ®Google Scholar
• Klewinghaus D, Pekar L, Arras P, Krah S, Valldorf B, Kolmar H, Zielonka S. Grabbing the bull by both horns: bovine ultralong CDR-H3 paratopes enable engineering of “almost natural” common light chain bispecific antibodies suitable for effector cell redirection. Front Immunol. 2021;12:801368. PMID:35087526. doi:10.3389/fimmu.2021.801368.
   PubMed Web of Science ®Google Scholar
• Klausz K, Pekar L, Boje AS, Gehlert CL, Krohn S, Gupta T, Xiao Y, Krah S, Zaynagetdinov R, Lipinski B, et al. Multifunctional NK cell–engaging antibodies targeting EGFR and NKp30 elicit efficient tumor cell killing and proinflammatory cytokine release. J Immunol. 2022;209(9):1724–35. PMID:36104113. doi:10.4049/jimmunol.2100970.
   PubMed Web of Science ®Google Scholar
• Alteber Z, Kotturi MF, Whelan S, Ganguly S, Weyl E, Pardoll DM, Hunter J, Ophir E. Therapeutic targeting of checkpoint receptors within the DNAM1 Axis. Cancer Discov. 2021;11(5):1040–51. PMID:33687987. doi:10.1158/2159-8290.CD-20-1248.
   PubMed Web of Science ®Google Scholar
• Trias E, Juan M, Urbano-Ispizua A, Calvo G. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transplant. 2022;57(2):156–59. PMID:35046545. doi:10.1038/s41409-021-01463-y.
   PubMed Web of Science ®Google Scholar
• Gurvich OL, Puttonen KA, Bailey A, Kailaanmäki A, Skirdenko V, Sivonen M, Pietikäinen S, Parker NR, Ylä-Herttuala S, Kekarainen T. Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products. Sci Rep. 2020;10(1):14049. PMID:32820219. doi:10.1038/s41598-020-70967-2.
   PubMed Web of Science ®Google Scholar
• Espie D, Donnadieu E. CAR T-cell behavior and function revealed by real-time imaging. Semin Immunopathol. 2023;45(2):229–39. PMID:36688965. doi:10.1007/s00281-023-00983-7.
   PubMed Web of Science ®Google Scholar
• Reiss K, Ueno N, Yuan Y, Johnson M, Dees EC, Chao J, Angelos M, Swaby R, Cushing D, Ronczka A, et al. 633 a phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors. J ImmunoTher Cancer. Internet. 2022;10. doi:10.1136/jitc-2022-SITC2022.0633.
   Web of Science ®Google Scholar
• Yu X, Chan HTC, Fisher H, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, French RR, Duriez PJ, Douglas LR, et al. Isotype switching converts Anti-CD40 antagonism to agonism to elicit potent antitumor activity. Cancer Cell. 2020;37(6):850–66.e7. PMID:32442402. doi:10.1016/j.ccell.2020.04.013.
   PubMed Web of Science ®Google Scholar
• Bertoglio F, Fühner V, Ruschig M, Heine PA, Abassi L, Klünemann T, Rand U, Meier D, Langreder N, Steinke S, et al. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep. 2021;36(4):109433. PMID:34273271. doi:10.1016/j.celrep.2021.109433.
   PubMed Web of Science ®Google Scholar
• Vicari AP, Schoepfer AM, Meresse B, Goffin L, Léger O, Josserand S, Guégan N, Yousefi S, Straumann A, Cerf-Bensussan N, et al. Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis. MAbs. 2017;9(6):927–44. PMID:28581883. doi:10.1080/19420862.2017.1332553.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yin C, Lum LG, Simons A, Weiner GJ. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. J Hematol Oncol. 2021;14(1):204. PMID:34886888. doi:10.1186/s13045-021-01216-w.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11(2):239–64. PMID:30543482. doi:10.1080/19420862.2018.1553476.
   PubMed Web of Science ®Google Scholar
• Falck D, Thomann M, Lechmann M, Koeleman CAM, Malik S, Jany C, Wuhrer M, Reusch D. Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody. MAbs. 2021;13(1):1865596. PMID:33382957. doi:10.1080/19420862.2020.1865596.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ptacin JL, Fischer EC, Aerni HR, Caffaro CE, San Jose K, Feldman AW, Turner CR, Romesberg FE. A semi-synthetic organism that stores and retrieves increased genetic information. Nature. 2017;551(7682):644–47. PMID:29189780. doi:10.1038/nature24659.
   PubMed Web of Science ®Google Scholar
• Largy E, Cantais F, Van Vyncht G, Beck A, Delobel A. Orthogonal liquid chromatography-mass spectrometry methods for the comprehensive characterization of therapeutic glycoproteins, from released glycans to intact protein level. J Chromatogr A. 2017;1498:128–46. PMID:28372839. doi:10.1016/j.chroma.2017.02.072.
   PubMed Web of Science ®Google Scholar
• Meunier S, de Bourayne M, Hamze M, Azam A, Correia E, Menier C, Maillère B. Specificity of the T cell response to protein biopharmaceuticals. Front Immunol. 2020;11:1550. PMID:32793213. doi:10.3389/fimmu.2020.01550.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Rosenberg AS, Miah SMS, Skowron G, Roberts BJ, Lélias S, Terry FE, Martin WD. Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses. Clin Immunol. 2021;224:108661. PMID:33412295. doi:10.1016/j.clim.2020.108661.
   PubMed Web of Science ®Google Scholar
• Van de Walle I, Silence K, Budding K, Van de Ven L, Dijkxhoorn K, de Zeeuw E, Yildiz C, Gabriels S, Percier J-M, Wildemann J, et al. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol. 2021;147(4):1420–9.e7. PMID:32926878. doi:10.1016/j.jaci.2020.08.028.
   PubMed Web of Science ®Google Scholar
• Guimaraes Koch SS, Thorpe R, Kawasaki N, Lefranc M-P, Malan S, Martin ACR, Mignot G, Plückthun A, Rizzi M, Shubat S, et al. International nonproprietary names for monoclonal antibodies: an evolving nomenclature system. MAbs. 2022;14(1):2075078. PMID:35584276. doi:10.1080/19420862.2022.2075078.
   PubMed Web of Science ®Google Scholar
• Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev. 2007;215(1):59–76. PMID:17291279. doi:10.1111/j.1600-065X.2006.00479.x.
   PubMed Web of Science ®Google Scholar
• André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731–43.e13. PMID:30503213. doi:10.1016/j.cell.2018.10.014.
   PubMed Web of Science ®Google Scholar
• Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190(2):167–72. PMID:9878117. doi:10.1006/cimm.1998.1396.
   PubMed Web of Science ®Google Scholar
• The European Medicines Agency. ICH Q6B specifications: test procedures and acceptance criteria for biotechnological/biological products - scientific guideline [Internet]. European Medicines Agency; 2018 [accessed 2023 Jan 12]. https://www.ema.europa.eu/en/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnological-biological-products
   Google Scholar
• Center for Drug Evaluation and Research. Coronavirus treatment acceleration program (CTAP). FDA [Internet]; 2022 [accessed 2023 Jan 12]. https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap
   Google Scholar
• Center for Drug Evaluation and Research. COVID-19: potency assay considerations for monoclonal antibodies and other therapeutic proteins targeting SARS-CoV-2 infectivity [Internet]. U.S. Food and Drug Administration; 2021 [accessed 2023 Jan 12]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-potency-assay-considerations-monoclonal-antibodies-and-other-therapeutic-proteins-targeting
   Google Scholar